GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (NAS:EXAS) » Definitions » Marketable Securities

EXAS (Exact Sciences) Marketable Securities : $432 Mil (As of Sep. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Exact Sciences Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Exact Sciences's Marketable Securities for the quarter that ended in Sep. 2024 was $432 Mil.

Exact Sciences's annual Marketable Securities declined from Dec. 2021 ($715 Mil) to Dec. 2022 ($390 Mil) and declined from Dec. 2022 ($390 Mil) to Dec. 2023 ($172 Mil).


Exact Sciences Marketable Securities Historical Data

The historical data trend for Exact Sciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Marketable Securities Chart

Exact Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 146.40 348.70 715.01 389.56 172.27

Exact Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 139.79 172.27 304.61 416.60 432.30

Exact Sciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Exact Sciences  (NAS:EXAS) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".


Exact Sciences Marketable Securities Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Sciences Business Description

Traded in Other Exchanges
Address
5505 Endeavor Lane, Madison, WI, USA, 53719
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Executives
Kevin T Conroy director, officer: Vice President 5505 ENDEAVOR LANE, MADISON WI 53719
Brian Baranick officer: Gen. Mgr., Precision Oncology 441 CHARMANY DRIVE, MADISON WI 53719
Jacob A Orville officer: General Manager, New Ventures 5505 ENDEAVOR LANE, MADISON WI 53719
James Herriott officer: General Counsel 5505 ENDEAVOR LANE, MADISON WI 53719
Sarah Condella officer: SVP, Human Resources 441 CHARMANY DRIVE, MADISON WI 53719
D Scott Coward officer: SVP and General Counsel 441 CHARMANY DRIVE, MADISON WI 53719
Jeffrey Thomas Elliott officer: Chief Financial Officer 5505 ENDEAVOR LANE, MADISON WI 53719
Everett Cunningham officer: Chief Commercial Officer C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Daniel J Levangie director 85 SWANSON ROAD, BOXBOROUGH MA 01719
James Edward Doyle director 5505 ENDEAVOR LANE, MADISON WI 53719
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Katherine S Zanotti director 431 E 9TH STREET, HINSDALE IL 60521
Paul J Clancy director C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Graham Peter Lidgard officer: SVP, Chief Scientific Officer 5505 ENDEAVOR LANE, MADISON WI 53719
Michael S Wyzga director RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139